Description
Retatrutide lyophilized powder for research use only. Bacteriostatic water not included; please order if needed.
Scientific Description and Mechanism
- Triple Agonism: Retatrutide uniquely activates three distinct receptors (GLP-1, GIP, and GCGR) to achieve comprehensive metabolic regulation.
- GIP (Glucose-dependent Insulinotropic Polypeptide): Enhances insulin secretion and reduces food intake.
- GLP-1 (Glucagon-like Peptide-1): Promotes satiety and delays gastric emptying.
- Glucagon Receptor (GCGR): Increases energy expenditure and promotes lipid mobilization (lipolysis).
- Structure and Pharmacokinetics: Retatrutide is a 39-amino acid synthetic peptide that includes three unnatural amino acids (two Aib, one
MeL) to enhance stability against enzymes like DPP4. It has a long half-life of approximately 6 days, allowing for once-weekly administration.
- Efficacy: Phase 2 clinical trials showed that at 48 weeks, participants with obesity lost an average of 24.4% of their body weight at the highest dose, with some losing over 70 lbs.
- Safety Profile: The most common adverse effects are gastrointestinal (nausea, diarrhea, vomiting), which are generally dose-related.
